Evid Invest
Who owns CYCNWhat CYCN owns — n/a

Who owns Cyclerion Therapeutics, Inc.?

Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.

Institutional ownership of CYCN from SEC Form 13F filings across 15 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.

As of the 2026-06-30 reporting period, 15 institutions disclosed 1.2M shares of Cyclerion Therapeutics, Inc. worth $3.8M — about 27.2% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.

15

13F holders

$3.8M

value, 2026 filers

27.2%

of shares outstanding (1.2M sh)

4

new positions (2026 filers)

Top institutional holders

ordered by shares owned · positions as of 2026-06-30· % of fund = share of the manager's own book · % of co. = share of CYCN's shares outstanding

#ManagerSharesValue% of fund% of co.Δ shares QoQ
1FMR LLC649,547$2.2M0.0%15.3%+13603.5%
2Balyasny Asset Management L.P.NEW317,511$1.1M0.0%7.5%new
3CITADEL ADVISORS LLC59,795$202,7050.0%1.4%+227.4%
4GEODE CAPITAL MANAGEMENT, LLC45,850$155,4710.0%1.1%-45.8%
5VANGUARD CAPITAL MANAGEMENT LLC30,915$104,8020.0%0.7%-4.2%
6HRT FINANCIAL LPNEW22,054$740.0%0.5%new
7BlackRock, Inc.16,797$56,9420.0%0.4%0.0%
8VANGUARD FIDUCIARY TRUST CO7,353$24,9270.0%0.2%0.0%
9UBS Group AG3,135$10,6270.0%0.1%-7.5%
10Tower Research Capital LLC (TRC)NEW1,849$6,2680.0%0%new
11OSAIC HOLDINGS, INC.130$4400.0%0%0.0%
12Activest Wealth Management100$3390.0%0%0.0%
13BARCLAYS PLCNEW87$2950.0%0%new
14WHI TRUST Co LLC72$2440.0%0%0.0%
15BNP PARIBAS FINANCIAL MARKETS4$140.0%0%-20.0%

Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.